AU2015283133B2 - Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime useful in methods of treating conditions related to the OT-R activity - Google Patents

Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime useful in methods of treating conditions related to the OT-R activity Download PDF

Info

Publication number
AU2015283133B2
AU2015283133B2 AU2015283133A AU2015283133A AU2015283133B2 AU 2015283133 B2 AU2015283133 B2 AU 2015283133B2 AU 2015283133 A AU2015283133 A AU 2015283133A AU 2015283133 A AU2015283133 A AU 2015283133A AU 2015283133 B2 AU2015283133 B2 AU 2015283133B2
Authority
AU
Australia
Prior art keywords
carbonyl
methyl
hydroxymethyl
biphenyl
crystalline compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015283133A
Other languages
English (en)
Other versions
AU2015283133A1 (en
Inventor
Andre Chollet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Obseva SA
Original Assignee
Obseva SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obseva SA filed Critical Obseva SA
Publication of AU2015283133A1 publication Critical patent/AU2015283133A1/en
Application granted granted Critical
Publication of AU2015283133B2 publication Critical patent/AU2015283133B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AU2015283133A 2014-07-02 2015-06-10 Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime useful in methods of treating conditions related to the OT-R activity Active AU2015283133B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462020076P 2014-07-02 2014-07-02
US62/020,076 2014-07-02
PCT/EP2015/062881 WO2016000920A1 (en) 2014-07-02 2015-06-10 Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity

Publications (2)

Publication Number Publication Date
AU2015283133A1 AU2015283133A1 (en) 2017-02-16
AU2015283133B2 true AU2015283133B2 (en) 2019-05-16

Family

ID=53434312

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015283133A Active AU2015283133B2 (en) 2014-07-02 2015-06-10 Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime useful in methods of treating conditions related to the OT-R activity

Country Status (13)

Country Link
US (2) US9718772B2 (enExample)
EP (2) EP3753921A1 (enExample)
JP (4) JP2017519015A (enExample)
KR (1) KR102470283B1 (enExample)
CN (3) CN106795110A (enExample)
AU (1) AU2015283133B2 (enExample)
CA (1) CA2953722C (enExample)
EA (2) EA031353B1 (enExample)
ES (1) ES2774789T3 (enExample)
IL (1) IL249652B (enExample)
MX (1) MX371068B (enExample)
UA (1) UA122210C2 (enExample)
WO (1) WO2016000920A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
UA122210C2 (uk) 2014-07-02 2020-10-12 Обсева С.А. Кристалічний о-метилоксим (3z,5s)-5-(гідроксиметил)-1-[(2'-метил-1,1'-біфеніл-4-іл)карбоніл]піролідин-3-oну, корисний у способах лікування станів, пов'язаних з активністю ot-r
AU2017205254B2 (en) 2016-01-04 2021-05-20 Xoma (Us) Lcc Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
WO2018015497A2 (en) 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CN114667141A (zh) * 2019-09-03 2022-06-24 奥布赛瓦股份公司 用于促进胚胎移植和预防流产的催产素拮抗剂给药方案
JP7083793B2 (ja) * 2019-09-10 2022-06-13 Ｊｆｅケミカル株式会社 パラターフェニルテトラカルボン酸およびパラターフェニルテトラカルボン酸二無水物の製造方法
WO2021160597A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy
EP4313061A4 (en) * 2021-03-31 2025-03-05 The Board of Trustees of the Leland Stanford Junior University FORMULATIONS FOR PROLONGATION OF GESTATION AND FOR COMPLICATIONS OF MENSTRUATION OR GESTATION

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845850A1 (en) * 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU120988A (en) 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
YU183988A (en) 1988-09-30 1990-08-31 Lek Tovarna Farmacevtskih Process for preparing dispersion pills of dihydroergotoxine
JP2927532B2 (ja) 1989-11-09 1999-07-28 塩野義製薬株式会社 含窒素異項環オキシーフェノキシ酢酸誘導体およびその除草剤としての用途
US5889001A (en) 1993-07-29 1999-03-30 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
JP3534903B2 (ja) 1995-06-09 2004-06-07 鐘淵化学工業株式会社 １−［３−クロロ−（２ｓ）−メチルプロピオニル］−ピロリジン−（２ｓ）−カルボン酸の製造方法
GB9603699D0 (en) 1996-02-21 1996-04-17 Boots Co Plc Therapeutic composition
US6696484B2 (en) 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
HK1046644B (en) 1999-12-09 2006-11-10 Reckitt Benckiser Healthcare (Uk) Limited Compressed tablet composition comprising a nsaid
PT1268418E (pt) 2000-03-27 2006-08-31 Applied Research Systems Derivados da pirrolidina farmacologicamente activos com inibidores bax
HRP20020705A2 (en) 2000-03-27 2004-12-31 Applied Research Systems Pharmaceutically active pyrrolidine derivatives
TW536751B (en) 2000-07-14 2003-06-11 Nitto Denko Corp Cleaning sheet, conveying member using the same, and substrate processing equipment cleaning method using them
DE60226431D1 (de) 2001-03-20 2008-06-19 Serono Lab Pyrrolidinesterderivate mit oxytocinmodulierender wirkung
KR200245627Y1 (ko) * 2001-05-15 2001-10-15 김병두 전기 가열부재가 부착된 냄비
CA2449578C (en) 2001-06-18 2011-12-13 Applied Research Systems Ars Holding N.V. Pyrrolidine oxadiazole- and thiadiazole derivatives
JP2003192582A (ja) 2001-12-12 2003-07-09 Merck Patent Gmbh ナプロキセンナトリウムを含む速放性錠剤
UA78058C2 (en) 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
ATE449067T1 (de) 2003-02-27 2009-12-15 Merck Serono Sa Pyrrolidin-derivate als oxytocin antagonisten
EA011026B1 (ru) 2004-02-26 2008-12-30 Лаборатуар Сероно Са Способ получения пирролидиноксимов
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
MX2007014022A (es) 2005-05-10 2008-02-07 Ferring Int Ct Sa Uso de antagonistas de oxitocina y/o vasopresina en la reproduccion asistida.
JP2008189732A (ja) 2007-02-01 2008-08-21 Fujifilm Corp セルロースアシレート組成物、セルロースアシレートフィルム、光学補償シート、偏光板および液晶表示装置
PL2572705T3 (pl) 2007-10-01 2018-01-31 Lesvi Laboratorios Sl Tabletki ulegające rozpadowi w jamie ustnej
US9201077B2 (en) 2009-07-27 2015-12-01 Colorado State University Research Foundation Direct enzyme immunoassay for measurement of serum progesterone levels
CA2892000A1 (en) 2012-11-26 2014-05-30 Piotr Pierzynski Method and system for diagnosing uterine contraction levels using image analysis
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
UA122210C2 (uk) 2014-07-02 2020-10-12 Обсева С.А. Кристалічний о-метилоксим (3z,5s)-5-(гідроксиметил)-1-[(2'-метил-1,1'-біфеніл-4-іл)карбоніл]піролідин-3-oну, корисний у способах лікування станів, пов'язаних з активністю ot-r
EP3501533B1 (en) 2014-12-22 2025-07-09 Ferring B.V. Obe001 for use in the treatment in implantation and pregnancy in women undergoing assisted reproductive technologies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845850A1 (en) * 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists

Also Published As

Publication number Publication date
KR102470283B1 (ko) 2022-11-23
EA201891873A1 (ru) 2019-04-30
EP3164384B1 (en) 2019-12-04
ES2774789T3 (es) 2020-07-22
US9718772B2 (en) 2017-08-01
US10752583B2 (en) 2020-08-25
EP3753921A1 (en) 2020-12-23
WO2016000920A1 (en) 2016-01-07
CA2953722C (en) 2022-09-13
US20170320822A1 (en) 2017-11-09
EA201790080A1 (ru) 2017-06-30
JP2017519015A (ja) 2017-07-13
CN106795110A (zh) 2017-05-31
IL249652B (en) 2021-09-30
CN114105850A (zh) 2022-03-01
MX2016016751A (es) 2017-08-08
US20160002160A1 (en) 2016-01-07
AU2015283133A1 (en) 2017-02-16
MX371068B (es) 2020-01-15
IL249652A0 (en) 2017-02-28
EP3164384A1 (en) 2017-05-10
UA122210C2 (uk) 2020-10-12
EA031353B1 (ru) 2018-12-28
CA2953722A1 (en) 2016-01-07
JP2023018037A (ja) 2023-02-07
CN114105851A (zh) 2022-03-01
KR20170023961A (ko) 2017-03-06
JP2025013885A (ja) 2025-01-28
JP2021038236A (ja) 2021-03-11

Similar Documents

Publication Publication Date Title
AU2015283133B2 (en) Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime useful in methods of treating conditions related to the OT-R activity
US20230097933A1 (en) Pyrrolidine derivatives as oxytocin/vasopressin v1a receptors antagonists
AU2014364962B2 (en) Oral formulations of pyrrolidine derivatives
HK40039130A (en) Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2’-methyl-1,1’-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity
HK1231866B (en) Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity
HK1231866A1 (en) Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity
BR112016030894B1 (pt) Composto cristalino, composição farmacêutica e método para preparar um composto cristalino
HK40086793A (en) Pyrrolidine derivatives as oxytocin/vasopressin v1a receptors antagonists
HK1247612B (en) Process for the preparation of (3z,5s)-5-(hydroxymethyl)-1-[(2 ́-methyl-1,1 ́-biphenyl-4-yl)carbonyl)pyrrolidin-3-one o-methyloxime
HK1221716B (en) (3z,5s)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl)pyrrolidin-3-one o-methyloxime as oxytocin / vasopressin v1a receptors antagonists for the treatment of preterm labor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
GM Mortgages registered

Name of requester: OXFORD FINANCE LLC